AXOGEN INC. - COMMON STOCK
12.54
13-November-24 16:45:00
15 minutes delayed
Stocks
-0.73
-5.50%
Today's range
12.51 - 13.38
ISIN
N/A
Source
NASDAQ
-
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire
-
02 Mar 2023 16:00:00 By Nasdaq GlobeNewswire
-
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire
-
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
09 Jan 2023 07:00:00 By Nasdaq GlobeNewswire
-
05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire
-
Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
04 Jan 2023 07:00:00 By Nasdaq GlobeNewswire
-
19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 Third Quarter Financial Results
08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire
-
Axogen to Participate at Upcoming Investor Conferences
03 Nov 2022 16:00:00 By Nasdaq GlobeNewswire
-
31 Oct 2022 07:00:00 By Nasdaq GlobeNewswire
-
20 Oct 2022 07:00:01 By Nasdaq GlobeNewswire
-
Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
22 Sep 2022 07:00:00 By Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 Second Quarter Financial Results
03 Aug 2022 16:01:01 By Nasdaq GlobeNewswire
-
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
29 Jul 2022 07:00:00 By Nasdaq GlobeNewswire
-
18 Jul 2022 16:00:00 By Nasdaq GlobeNewswire
-
Axogen, Inc. Appoints William Burke to Board of Directors
11 Jul 2022 07:00:00 By Nasdaq GlobeNewswire
-
18 May 2022 07:00:00 By Nasdaq GlobeNewswire
-
Axogen, Inc Reports 2022 First Quarter Financial Results
04 May 2022 16:05:01 By Nasdaq GlobeNewswire
-
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
04 May 2022 16:01:00 By Nasdaq GlobeNewswire
-
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
13 Apr 2022 07:00:00 By Nasdaq GlobeNewswire